pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,561 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints785BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6110Rare Disease1467Cardiology1094Hematology1031Immunology1020Vaccines919Pulmonology
  • Georgia entrepreneur struggles to afford health insurance after decades of self‑employment
    Amy Bielawski, a 61‑year‑old owner of an entertainment company in Tucker, Georgia, has spent most of her adult life without health insurance. For 32 years she has run a business that provides bounc…
    STAT · 1mo agoNegative↗ source
  • Vertex to buy Crinetics for $10 billion, adding acromegaly drug Palsonify
    Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, marking the largest deal in Vertex’s history. The purchase gives Vertex control of Crinetics’ marketed ther…
    STAT · 1mo agoDealPositive↗ source
← prev
page 49 of 103
next →
73
fda recalls48
fda medwatch41
fda press28
911
Psychiatry & CNS725
Ophthalmology424
Pain406
Endocrinology & Metabolism390
Infectious Disease361
  • Vertex to acquire Crinetics in $10 billion deal to expand endocrinology portfolio
    Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $10 billion, the largest purchase in the company's history. The transaction is aimed at broadening Vertex's commercia…
    Endpoints · 1mo agoDealPositive↗ source
  • AbbVie completes $10.9 billion acquisition of Apogee Therapeutics as UK launches drug pricing pilot
    AbbVie, the Chicago-based pharmaceutical company, finalized its purchase of Apogee Therapeutics for $10.9 billion last month, ending a multi-year negotiation process. The transaction brings Apogee…
    Endpoints · 1mo agoDealPositive↗ source
  • FDA approves 23 new drugs in first half, marking best pace in three years despite staff cuts
    The FDA announced that it has approved 23 novel drugs during the first half of 2026, the strongest approval count in three years. The approvals come after the Trump administration reduced FDA staf…
    Endpoints · 1mo agoApprovalPositive↗ source
  • Novartis to buy Myricx Bio for up to $1.5 billion, adding two novel ADCs to its oncology portfolio
    Novartis announced it will acquire Myricx Bio, a UK‑based biotech that develops antibody drug conjugates (ADCs), in a move to broaden its oncology pipeline. The transaction is valued at up to $1.5…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • CMS proposes rule to slash Medicare 340B drug payments by over a third
    CMS announced a proposed rule that would reduce the rates Medicare uses to reimburse hospitals for drugs purchased through the 340B program. The reduction would be more than one-third, effectively…
    Endpoints · 1mo agoRegulatoryNegative↗ source
  • Study finds many telehealth sites prescribe GLP-1 weight-loss drugs with minimal clinical oversight
    A secret-shopper investigation examined 49 direct-to-consumer telehealth platforms that offer GLP-1 medicines such as semaglutide and tirzepatide for weight loss. Researchers posing as patients fo…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Novartis to buy Myricx Bio for $1.1 billion as Medicare proposes steep 340B cuts and other biotech policy updates
    Novartis announced it will acquire UK‑based Myricx Bio for an upfront $1.1 billion, adding an antibody‑drug conjugate platform aimed at solid‑tumor cancers. The agreement also includes potential mi…
    STAT · 1mo agoDealNeutral↗ source
  • Cancer and immune-focused biotech firms capture over $3.9 billion of H1 2026 venture capital
    BioPharma Dive data show that cancer and immune disease biotech companies accounted for more than 40% of the biotech firms receiving venture funding in the first half of 2026. Of the roughly $9 bi…
    BioPharma Dive · 1mo agoDealNeutral↗ source
  • Novartis to spend $1.1 billion upfront acquiring Myricx Bio and its next-gen ADC platform
    Novartis announced Monday it will invest $1.1 billion in an upfront payment to acquire Myricx Bio. Myricx Bio brings an antibody-drug conjugate (ADC) payload platform that the Swiss group believes…
    Endpoints · 1mo agoDealPositive↗ source
  • Bristol Myers reports Krazati confirmatory trial fails in colorectal cancer
    Bristol Myers Squibb disclosed that the confirmatory study of its investigational drug Krazati in combination with an EGFR inhibitor did not achieve its primary efficacy endpoints in patients with…
    Endpoints · 1mo agoCRLNegative↗ source
  • Roche partners with Otsuka's Astex in $25 million deal to strengthen breast cancer pipeline
    Roche's Genentech subsidiary has signed a collaboration with Astex Pharmaceuticals, a unit of Otsuka, that includes a $25 million upfront payment. The partnership is an early‑stage effort aimed at…
    Endpoints · 1mo agoDealPositive↗ source
  • Gene-editing biotech Scribe Therapeutics files for Nasdaq IPO
    Scribe Therapeutics, a California-based biotechnology startup developing genetic medicines for cardiometabolic disorders, announced plans to go public on the Nasdaq under the ticker SCTX. The comp…
    BioPharma Dive · 1mo agoDealNeutral↗ source
  • Novartis to acquire Myricx Bio for $1.1 billion to expand antibody-drug conjugate pipeline
    Novartis announced it will buy London-based Myricx Bio, agreeing to pay $1.1 billion upfront. The deal gives Novartis access to Myricx's novel payload technology - an N-myristoyltransferase inhibi…
    STAT · 1mo agoDealPositive↗ source
  • Former Surgeon General Calls for Clinician-Guided Framework to Regulate Popular Peptides
    Jerome Adams, the former U.S. surgeon general, argues that the FDA should adopt a middle‑ground strategy rather than banning peptide compounds outright. He notes the rapid growth of peptide use for…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • ACA enrollment falls sharply, with Ohio and Oklahoma each losing about a third of participants
    New federal data shows steep drops in Affordable Care Act enrollment across the United States, with Ohio and Oklahoma each losing nearly one‑third of their participants. Overall, about 2.6 million…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Lancaster County emerges as new biotech hub as Boston faces layoffs
    Boston’s biotech sector is experiencing layoffs and vacant lab space, signaling a slowdown in the region that has long been a biotech stronghold. In contrast, Lancaster County, Pennsylvania, is wi…
    BioPharma Dive · 1mo agoNeutral↗ source
  • Ebola therapy development accelerates as multiple candidates enter early trials
    A new wave of research teams are racing to develop a therapy for Ebola, according to the latest Morning Rounds newsletter. The article notes that several candidates are now moving into early‑stage…
    STAT · 1mo agoNeutral↗ source
  • FDA CDER appoints veteran GLP-1 reviewer Lisa Yanoff as acting deputy director
    Acting FDA CDER director Michael Davis promoted Lisa Yanoff to the role of acting deputy director of the Center for Drug Evaluation and Research. Yanoff is a long‑time FDA employee with deep exper…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Salk Institute President Warns of NIH Funding Cuts While Embracing AI and Brain Research Initiatives
    Gerald Joyce, president of the Salk Institute, highlighted recent reductions in NIH funding and their impact on research institutions. He said the institute is fully committing resources to artifi…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Opinion: Stopping doctors from ordering unnecessary diagnostic tests requires a structural fix
    “The medical industry has spent enormous effort making more advanced tests but expended little effort learning how to use tests correctly,” writes Daniel Morgan.
    STAT · 1mo ago↗ source
  • STAT+: GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse
    Supporters say clinical trial diversity is about making sure drugs and devices work, not about DEI.
    STAT · 1mo ago↗ source
  • STAT+: I spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learned
    Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology right now.
    STAT · 1mo ago↗ source
  • What does content creation do to mental health?
    This year at Vidcon, I was struck by how much of the conference’s programming was dedicated to the mental health of content creators.
    STAT · 1mo ago↗ source